X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21117) 21117
Magazine Article (168) 168
Book / eBook (60) 60
Book Chapter (29) 29
Web Resource (23) 23
Publication (19) 19
Book Review (10) 10
Conference Proceeding (10) 10
Dissertation (3) 3
Paper (2) 2
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19729) 19729
fibrinolytic agents - therapeutic use (18133) 18133
male (9140) 9140
female (8507) 8507
middle aged (6466) 6466
aged (6187) 6187
treatment outcome (4744) 4744
tissue plasminogen activator - therapeutic use (4038) 4038
adult (3667) 3667
thrombolytic therapy (3545) 3545
fibrinolytic agents - administration & dosage (3305) 3305
peripheral vascular disease (3142) 3142
anticoagulants - therapeutic use (3095) 3095
risk factors (3017) 3017
fibrinolytic agents - adverse effects (3008) 3008
myocardial infarction - drug therapy (2803) 2803
animals (2783) 2783
cardiac & cardiovascular systems (2753) 2753
stroke (2748) 2748
time factors (2695) 2695
thrombolysis (2442) 2442
stroke - drug therapy (2428) 2428
aged, 80 and over (2355) 2355
clinical neurology (2239) 2239
heparin - therapeutic use (2050) 2050
platelet aggregation inhibitors - therapeutic use (2018) 2018
thrombolytic therapy - methods (1905) 1905
retrospective studies (1796) 1796
therapy (1793) 1793
hematology (1762) 1762
thrombosis (1728) 1728
fibrinolytic agents - pharmacology (1715) 1715
aspirin - therapeutic use (1690) 1690
medicine, general & internal (1659) 1659
thrombosis - drug therapy (1575) 1575
surgery (1480) 1480
acute disease (1437) 1437
streptokinase - therapeutic use (1427) 1427
mortality (1360) 1360
prospective studies (1358) 1358
care and treatment (1320) 1320
brain ischemia - drug therapy (1292) 1292
drug therapy, combination (1274) 1274
anticoagulants (1257) 1257
follow-up studies (1228) 1228
pharmacology & pharmacy (1213) 1213
management (1192) 1192
myocardial infarction - therapy (1166) 1166
prognosis (1159) 1159
recombinant proteins - therapeutic use (1143) 1143
tissue plasminogen activator - administration & dosage (1136) 1136
aspirin (1124) 1124
risk (1111) 1111
prevention (1108) 1108
acute ischemic-stroke (1107) 1107
clinical trials as topic (1096) 1096
tissue plasminogen activator (1075) 1075
randomized controlled trials as topic (1061) 1061
electrocardiography (1040) 1040
tissue-plasminogen activator (1023) 1023
pulmonary embolism - drug therapy (1017) 1017
heparin (1006) 1006
abridged index medicus (994) 994
acute myocardial-infarction (990) 990
drug therapy (986) 986
hemorrhage - chemically induced (980) 980
risk assessment (964) 964
trial (962) 962
recurrence (919) 919
fibrinolysis (912) 912
thrombosis - prevention & control (910) 910
heparin, low-molecular-weight - therapeutic use (898) 898
ischemia (892) 892
stroke - etiology (879) 879
myocardial infarction - mortality (870) 870
medicine & public health (864) 864
neurosciences (856) 856
stroke - prevention & control (828) 828
alteplase (810) 810
molecular-weight heparin (807) 807
thromboembolism (797) 797
analysis (786) 786
adolescent (773) 773
rats (764) 764
urokinase-type plasminogen activator - therapeutic use (764) 764
stroke - therapy (762) 762
thrombosis - etiology (759) 759
practice guidelines as topic (755) 755
angioplasty, balloon, coronary (753) 753
tomography, x-ray computed (749) 749
health aspects (733) 733
thrombolytic therapy - adverse effects (733) 733
cardiology (726) 726
anticoagulants - adverse effects (704) 704
combined modality therapy (691) 691
warfarin (691) 691
neurology (690) 690
myocardial infarction (686) 686
dose-response relationship, drug (680) 680
heart attacks (676) 676
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (40) 40
Online Resources - Online (23) 23
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Mt Sinai Hospital - Online (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18123) 18123
German (784) 784
French (701) 701
Russian (421) 421
Spanish (400) 400
Italian (325) 325
Japanese (206) 206
Polish (139) 139
Chinese (134) 134
Dutch (59) 59
Portuguese (57) 57
Danish (51) 51
Hungarian (46) 46
Finnish (40) 40
Czech (31) 31
Swedish (26) 26
Norwegian (23) 23
Romanian (21) 21
Bulgarian (19) 19
Turkish (19) 19
Hebrew (18) 18
Ukrainian (18) 18
Croatian (9) 9
Lithuanian (9) 9
Serbian (9) 9
Slovak (7) 7
Korean (2) 2
Afrikaans (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Medicinal Chemistry, ISSN 0929-8673, 08/2015, Volume 22, Issue 24, pp. 2819 - 2857
Heterocyclic N-oxides have emerged as potent compounds with anticancer, antibacterial, antihypertensive, antiparasitic, anti-HIV, anti-inflammatory,... 
Antichagasic agents | Heterocyclic N-oxides | Bioisosteres | Factor xa inhibitors | Antimalarials | Hypoxia | Nitric oxide mimics | Coagulation cascade direct thrombin inhibitors | hypoxia | TRANSITION-METAL CATALYSIS | BETA-AMINOESTER CLASS | CHEMISTRY, MEDICINAL | ACTIVATED PROTEIN-KINASE | antichagasic agents | K-ATP CHANNELS | BIOCHEMISTRY & MOLECULAR BIOLOGY | antimalarials | HUMAN-LEUKOCYTE ELASTASE | coagulation cascade direct thrombin inhibitors | CARBON BOND FORMATION | 1,3-DIOXIDE CORE SCAFFOLDS | HIV-1 ENTRY INHIBITORS | PHARMACOLOGY & PHARMACY | bioisosteres | factor Xa inhibitors | LONG-TERM POTENTIATION | FACTOR XA INHIBITOR | nitric oxide mimics | Anti-HIV Agents - pharmacology | Neuroprotective Agents - therapeutic use | Antihypertensive Agents - pharmacology | Humans | Antineoplastic Agents - therapeutic use | Herbicides - pharmacology | Antihypertensive Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Fibrinolytic Agents - pharmacology | Cyclic N-Oxides - therapeutic use | Animals | Neuroprotective Agents - pharmacology | Cyclic N-Oxides - pharmacology | Protein Kinase Inhibitors - therapeutic use | Fibrinolytic Agents - therapeutic use | Anti-HIV Agents - therapeutic use | Anti-Bacterial Agents - pharmacology | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology
Journal Article
Trends in biotechnology (Regular ed.), ISSN 0167-7799, 2004, Volume 22, Issue 3, pp. 142 - 146
...-adhesive agents to pathogens, making them useful for treating many diseases and as therapeutic and probiotic agents... 
IN-VITRO | ITURIN-A | ANTIBIOTICS | ACTIVATION | BACILLUS-SUBTILIS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ENHANCEMENT | MANNOSYLERYTHRITOL LIPIDS | BIOSURFACTANTS | GENE TRANSFECTION | PLASMINOGEN | Fibrinolysis - drug effects | Surface-Active Agents - therapeutic use | Antibiotics, Antineoplastic - pharmacology | Gram-Positive Bacteria - drug effects | Anti-Infective Agents - pharmacology | Humans | Peptides, Cyclic - pharmacology | Peptides, Cyclic - chemistry | Antifungal Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Anti-Infective Agents - chemistry | Fibrinolytic Agents - therapeutic use | Glycolipids - chemistry | Bacterial Adhesion - drug effects | Antifungal Agents - pharmacology | Antiviral Agents - pharmacology | Peptides - chemistry | Antiviral Agents - therapeutic use | Glycolipids - pharmacology | Anti-Infective Agents - therapeutic use | Peptides - pharmacology | Surface-Active Agents - pharmacology | Fibrinolytic Agents - pharmacology | Antibiotics, Antineoplastic - therapeutic use | Cell Differentiation - drug effects | Lipoproteins - pharmacology | Peptides, Cyclic - therapeutic use | Anti-Bacterial Agents - pharmacology | Surface-Active Agents - chemistry | Lipopeptides | Peptides - therapeutic use | Salmonella | Signal transduction | Probiotics | E coli | Herpes viruses | Antimicrobial agents | Lipids | Genetic engineering | Drug resistance | Surfactants | Bacteriology
Journal Article
Marine drugs, ISSN 1660-3397, 2019, Volume 17, Issue 9, p. 487
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
.... Our aim was to compare the use of rivaroxaban for extended thromboprophylaxis with short-term thromboprophylaxis with enoxaparin... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Marine drugs, ISSN 1660-3397, 2011, Volume 9, Issue 10, pp. 1761 - 1805
Sea cucumbers, belonging to the class Holothuroidea, are marine invertebrates, habitually found in the benthic areas and deep seas across the world. They have... 
Functional peptides | Biological activities | Sea cucumber bioactives | Triterpene glycosides | Glycosaminoglycan | Antioxidant nutrients | Medicinal health functions | sea cucumber bioactives | FUCOSE BRANCHES | CHEMISTRY, MEDICINAL | functional peptides | ACE INHIBITORY PEPTIDE | FUCOSYLATED CHONDROITIN SULFATE | CYTOTOXIC TRITERPENE GLYCOSIDES | HOT-WATER EXTRACTS | STICHOPUS-JAPONICUS | POLYSACCHARIDE ACCOUNT | antioxidant nutrients | biological activities | IN-VITRO | medicinal health functions | POLYUNSATURATED FATTY-ACIDS | ANTICOAGULANT ACTIVITIES | triterpene glycosides | glycosaminoglycan | Sea Cucumbers - chemistry | Anti-Infective Agents - isolation & purification | Nutritive Value | Anti-Infective Agents - therapeutic use | Anticoagulants - therapeutic use | Fisheries | Stichopus - metabolism | Antineoplastic Agents - therapeutic use | Antihypertensive Agents - therapeutic use | Fibrinolytic Agents - isolation & purification | Holothuria - chemistry | Stichopus - chemistry | Cucumaria - metabolism | Animals | Antihypertensive Agents - isolation & purification | Antineoplastic Agents - isolation & purification | Cucumaria - chemistry | Fibrinolytic Agents - therapeutic use | Holothuria - metabolism | Sea Cucumbers - metabolism | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - isolation & purification | Seafood - analysis | Anticoagulants - isolation & purification
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2018, Volume 2019, Issue 2, p. CD006649
...; checking of references of included studies; use of the 'related citation' feature in PubMed... 
'ORPHAN' TOPICS CURRENTLY BEING ADDRESSED | Anticoagulants | Recurrence | Tinzaparin | Secondary Prevention | Heparin, Low‐Molecular‐Weight | Fibrinolytic Agents | Hemorrhage | Neoplasms | Randomized Controlled Trials as Topic | Thrombophilia & other causes of thrombosis | Polysaccharides | Venous Thromboembolism | Dalteparin | Treatment of miscellaneous conditions in cancer | Fondaparinux | Heparin | Heart & circulation | Medicine General & Introductory Medical Sciences | Thrombo‐embolism prevention & treatment | General cancer treatments | Cancer | Fibrinolytic Agents [therapeutic use] | EXTERNAL PNEUMATIC COMPRESSION | RISK-FACTORS | STANDARD HEPARIN | Venous Thromboembolism [drug therapy; mortality] | Humans | RANDOMIZED CLINICAL-TRIAL | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | INTRAVENOUS UNFRACTIONATED HEPARIN | FACTOR-BEARING MICROPARTICLES | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | Polysaccharides [therapeutic use] | Dalteparin [therapeutic use] | LONG-TERM TINZAPARIN | Heparin [therapeutic use] | Heparin, Low-Molecular-Weight [therapeutic use] | Neoplasms [complications] | Anticoagulants [therapeutic use] | Polysaccharides - therapeutic use | Venous Thromboembolism - mortality | Anticoagulants - therapeutic use | Heparin - therapeutic use | Heparin, Low-Molecular-Weight - therapeutic use | Venous Thromboembolism - drug therapy | Neoplasms - complications | Dalteparin - therapeutic use | Fibrinolytic Agents - therapeutic use | Hemorrhage - chemically induced
Journal Article